Dr. Devasis Panda

Professional Journey

ACHIEVEMENTS

• Topper of the Odisha state in Xth Board Examination.
• Presented oral paper at European Society for Clinical Cell Analysis (ESCCA) annual conference 2019 on “Flow cytometric assay for immune cell profiling in post allogenic bone marrow transplant immune reconstitution studies” at Bergen, Norway.

AWARDS

• First prize for Best Clinical Science Poster presentation at the 12th Annual Conference of The Cytometry Society, India held at SGPGI, Lucknow (2019).
• First prize for best oral paper presentation at the Quarterly meeting of Mumbai Hematology Group at Seth GS Medical College and KEM Hospital (2019).
• First prize for best oral paper presentation at the Annual Conference of Thane Hematology Group at Jupiter Hospital (2019).
• Fourth prize for poster presentation at the 2nd Annual Conference of Indian Myeloma Congress held at ACTREC, Tata Memorial Hospital (2019).

 NOTABLE PUBLICATIONS

• Panda D, Chatterjee G, Khanka T, Ghogale S, Badrinath Y, Deshpande N, Sardana R, Chaturvedi A, Rajpal S, Shetty D, Patkar NV, Gujral S, Subramanian PG, Tembhare PR. Mast cell differentiation of leukemic blasts in diverse myeloid neoplasms: A potential pre-myelomastocytic leukemia condition. Cytometry B Clin Cytom. 2021 May;100(3):331-344.
• Panda D, Chatterjee G, Sardana R, Khanka T, Ghogale S, Deshpande N, Badrinath Y, Shetty D, Narula G, Banavali S, Patkar NV, Gujral S, Subramanian PG, Tembhare PR. Utility of CD36 as a novel addition to the immunophenotypic signature of RAM-phenotype acute myeloid leukemia and study of its clinicopathological characteristics. Cytometry B Clin Cytom. 2021 Mar;100(2):206-217.
• Panda D, Tejwani N, Pandey P, Mehta A, Rainchwar S, Panda T, Halder R, Palatty RJ, Agrawal N, Bhurani D. Myeloid sarcoma with RAM phenotype in an adult male presenting with CNS relapse; no longer a pediatric disease. Ann Hematol. 2024 Apr 27.
• Panda D, Pathak A, Tejwani N, Mehta A. Extranodal NK/T-cell lymphoma with isolated central nervous system relapse: A defiant disease and the role of flow cytometry in monitoring. Cytometry B Clin Cytom. 2023 May 4.
• Panda D, Pathak A, Tejwani N, Mehta A. A novel case of primary myelofibrosis with mastocytic differentiation; the characteristic CD117 vs HLA-DR dot plot on flow cytometry. Int J Lab Hematol. 2023 Feb 24.
• Panda D, Pathak A, Tejwani N, Pandey P, Mehta A. Acquired RUNX1::CBFA2T2 fusion at extramedullary relapse in a patient of PDGFRA rearranged acute myeloid leukemia post allogenic HSCT. Cytometry B Clin Cytom. 2023 Apr 13.
• Panda D, Das N, Thakral D, Gupta R. Genomic landscape of mature B-cell non-Hodgkin lymphomas – an appraisal from lymphomagenesis to drug resistance. J Egypt Natl Canc Inst. 2022 Dec 12;34(1):52.
• Das N, Panda D, Gajendra S, Gupta R, Thakral D, Kaur G, Khan A, Singh VK, Vemprala A, Bakhshi S, Seth R, Sahoo RK, Sharma A, Rai S, Prajapati VK, Singh S. Immunophenotypic characterization of leukemic stem cells in acute myeloid leukemia using single tube 10-colour panel by multiparametric flow cytometry: Deciphering the spectrum, complexity and immunophenotypic heterogeneity. Int J Lab Hematol. 2024 Mar 8.
• Panda D, Pathak A, Tejwani N, Mehta A. NK-cell trogocytosis of CD19 antigen: a rare B-ALL MRD mimicker. Blood Res. 2022 Dec 31;57(4):249.
• Panda D, Mukhopadhyay D, Datta C, Chattopadhyay BK, Chatterjee U, Shinde R. Inflammatory Myofibroblastic Tumor Arising in the Pancreatic Head: a Rare Case Report. Indian J Surg. 2015 Dec;77(6):538-40.
• Pathak A, Panda D, Sharma M, Tejwani N, Mehta A. Blood Donation Screening of Transfusion-Transmissible Viral Infection Using Two Different Nucleic Acid Testing (NAT) Platforms: A Single Tertiary Care Oncology Centre Experience. Indian J Hematol Blood Transfus. 2023 Jul;39(3):456-463.
• Tembhare PR, Sriram H, Khanka T, Chatterjee G, Panda D, Ghogale S, Badrinath Y, Deshpande N, Patkar NV, Narula G, Bagal B, Jain H, Sengar M, Khattry N, Banavali S, Gujral S, Subramanian PG. Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy. J Immunother Cancer. 2020 May;8(1):e000630.
• Pathak, A., Panda, D., Tejwani, N., & Mehta, A. A study on beneficial impact of the use of medium-molecular-weight hydroxyethyl starch in granulocyte apheresis using continuous-flow cell separator Spectra Optia: A retrospective single-center study at a tertiary care oncology center. Asian Journal of Transfusion Science, 10-4103.
• Gajendra, Smeeta, Shilpa Anupurba, Ritu Gupta, Saumyaranjan Mallick, Devasis Panda, Deepshi Thakral, Sanjeev Kumar Gupta et al. “Acute myeloid leukemia with RAM immunophenotype: A new underdiagnosed entity.” International Journal of Laboratory Hematology 45, no. 4 (2023): 541-552.
• Chatterjee G, Sriram H, Ghogale S, Deshpande N, Khanka T, Panda D, Pradhan SN, Girase K, Narula G, Dhamane C, Malik NR, Banavali S, Patkar NV, Gujral S, Subramanian PG, Tembhare PR. Immunophenotypic shift in the B-cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B-lymphoblastic leukemia. Cytometry B Clin Cytom. 2021 Jul;100(4):434-445.
• Tembhare PR, Chatterjee G, Khanka T, Ghogale S, Badrinath Y, Deshpande N, Panda D, Patkar NV, Narula G, Girase K, Verma S, Sanyal M, Sriram HN, Banavali S, Gujral S, Subramanian PG. Eleven-marker 10-color flow cytometric assessment of measurable residual disease for T-cell acute lymphoblastic leukemia using an approach of exclusion. Cytometry B Clin Cytom. 2021 Jul;100(4):421-433.